Le Lézard
Classified in: Health, Science and technology, Business
Subject: FNC

Orthogon Therapeutics Raises $4.4 Million in Series A Financing


CANTON, Mass., March 8, 2018 /PRNewswire-iReach/ -- Orthogon Therapeutics, LLC, a drug design company developing a pipeline of preclinical assets, announced today the closing of a $4.4 million Series A financing.  The investment round was co-led by Over-the-Rhine Ventures of Cincinnati, Ohio as well as Holbrook Angels of Boston, Massachusetts. The new funding will be used to advance the discovery of a portfolio of high-value lead drug candidates including nomination of the Company's first pre-clinical candidate for the treatment of viral infections in organ transplant recipients. 

'We are very pleased to have attracted a strong group of investors who recognize the potential of the Orthogon technology platform in adding value to the early stages of drug development,' said Ali Munawar, CEO of Orthogon. Mr. Munawar was previously the founding CEO of Novira Therapeutics, Inc., acquired by Johnson & Johnson in 2015.

In conjunction with the financing, Dr. P. A. Mehta, will join the Orthogon Board of Directors. 'Orthogon is a transformative drug discovery engine,' said Dr. Mehta, Managing Partner of Over-the-Rhine Ventures. Dr. Mehta went on to state the following, 'We are excited to support experienced life sciences entrepreneurs who are motivated by a desire to improve the lives of patients."

About Orthogon Therapeutics, LLC

Orthogon Therapeutics is a pre-clinical stage, drug design company that leverages a constellation of innovative technologies to discover and develop small molecules that modulate challenging but sought-after drug targets. The Company mission is to efficiently produce high-quality, medicinal, lead molecules that can be developed in a partnership model.

For additional information about Orthogon Therapeutics, please visit www.orthogontherapeutics.com.

Contact: Ali H. Munawar
Title: Chief Executive Officer & Founder
Company: Orthogon Therapeutics, LLC
Phone: 1-339-502-9108
Email: [email protected]

Media Contact: Ali Munawar, Orthogon Therapeutics, LLC, 339-502-9108, [email protected]

News distributed by PR Newswire iReach: https://ireach.prnewswire.com

SOURCE Orthogon Therapeutics, LLC


These press releases may also interest you

at 09:47
TotalEnergies Marketing USA and OK Petroleum announce strategic partnership to bring high performance products to Long Island, NY
TotalEnergies Marketing USA, a leading provider of high-performance lubricants and specialty fluids, today announced a strategic partnership with OK Petroleum, a well-respected distributor in Long Island, NY. This collaboration will bring...

at 09:43
NEW WAYS TO BLOOM. Beekman 1802's #1 Global Bestselling Moisturizer Just Got Even Better! This Skin Barrier Savior Is Now Kinder & More Accessible Than Ever Before
Discover new ways to make your skin BLOOM! Beekman 1802's top selling skin barrier-building formula, Bloom Cream Daily Face Moisturizer, is now available in two NEW formats that will make blooming even better! Introducing the Bloom Cream in a Tube...

at 09:37
Desenio's AI tool empowers customers to create their own art
Desenio has taken their passion for democratizing art to new heights by proudly launching their Imaginator AI creator, a groundbreaking AI art tool that empowers customers to dream up unique art for their walls.  ...

at 09:36
Pennsylvania Home Sales and Median Price Were Up in March
The spring homebuying market took off in March, with sales, listings and the median sales price all increasing from February, according to a report prepared for the Pennsylvania Association of Realtors®....

at 09:32
Power Corporation to Announce First Quarter 2024 Financial Results on May 8, 2024
Power Corporation of Canada (Power Corporation) will release its first quarter 2024 financial results on Wednesday, May 8, 2024, after markets close. R. Jeffrey Orr, President and Chief Executive Officer, and Jake Lawrence, Executive...

at 09:30
E SPLIT CORP. Completes Overnight Offering        
Middlefield, on behalf of E Split Corp. (the "Company"), is pleased to announce the Company has completed the overnight offering of class A and preferred shares (the "Class A Shares" and "Preferred Shares", respectively) for aggregate gross proceeds...

More news about Business...


News published on and distributed by: